Human immunodeficiency virus type 1 protease · SINGLE PROTEIN · Human immunodeficiency virus 1
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Human immunodeficiency virus type 1 protease shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 14 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q72874. Start with HIV infection, then reuse UniProt Q72874 as the stable protein anchor across project notes and exports.
Start with HIV infection, then reuse UniProt Q72874 as the stable protein anchor across project notes and exports.
Human immunodeficiency virus type 1 protease shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 14 linked drugs remain visible in the same block.
Start review with HIV infection because it currently carries approved-linked support. Linked drugs include AMPRENAVIR, ATAZANAVIR SULFATE, BRECANAVIR, DARUNAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPol polyprotein
Review this target as Human immunodeficiency virus type 1 protease, mapped to UniProt Q72874. ChEMBL maps the protein component as Pol polyprotein. Sequence length is 99 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Human immunodeficiency virus type 1 protease as ChEMBL target CHEMBL243, mapped to UniProt Q72874. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Human immunodeficiency virus type 1 protease is the right protein anchor across sources, using UniProt Q72874 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why HIV infection is currently framed as approved-linked support. It currently carries 14 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Human immunodeficiency virus type 1 protease |
| Target Type | SINGLE PROTEIN |
| Organism | Human immunodeficiency virus 1 |
| UniProt | Q72874 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Pol polyprotein |
| UniProt Accession | Q72874 |
| Component Type | Protein |
| Sequence Length | 99 aa |
Pol polyprotein
Review this target as Human immunodeficiency virus type 1 protease, mapped to UniProt Q72874. ChEMBL maps the protein component as Pol polyprotein. Sequence length is 99 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Human immunodeficiency virus type 1 protease shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block.
Start review with HIV infection because it currently carries approved-linked support. Linked drugs include AMPRENAVIR, ATAZANAVIR SULFATE, BRECANAVIR, DARUNAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1323 | 11.0 | Ki | 0.01 | Approved |
| CHEMBL182611 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL305125 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL333781 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL360212 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL361443 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL364376 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL364409 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL36900 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL405187 | 11.0 | Ki | 0.01 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 773 | 4,400 | 7.9 |
| assay format | 102 | 461 | 7.9 |
| cell-based format | 32 | 57 | 7.4 |
| organism-based format | 6 | 31 | 7.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 37 | 82 | 6.6 |
| assay format | 24 | 53 | 7.2 |